Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

by | Feb 20, 2026 | Health

Spread the love
The all-oral, fixed-duration treatment combination provided better PFS and safety than investigator’s choice of chemoimmunotherapy in the phase 3 AMPLIFY study.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments